Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 16 · inside the Ichimoku cloud · RSI 41 · MACD below its signal
| 8.77 | 52-week high | +205.57% |
| 3.72 | Previous month high | +29.62% |
| 3.35 | Previous week high | +16.72% |
| 3.25 | R3 (classic) | +13.24% |
| 3.16 | R2 (classic) | +10.10% |
| 3.07 | Previous day high | +6.97% |
| 3.01 | R1 (classic) | +5.05% |
| 2.92 | Pivot | +1.92% |
| 2.87 | Price now | |
| 2.84 | Previous day low | −1.22% |
| 2.84 | Previous week low | −1.22% |
| 2.78 | S1 (classic) | −3.14% |
| 2.69 | S2 (classic) | −6.27% |
| 2.55 | S3 (classic) | −11.32% |
| 2.37 | Previous month low | −17.42% |
| 2.15 | 52-week low | −25.09% |
None of the 29 investors followed here reported a position in QTRX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a QTRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Donnelly William PDirector | Stock Award(Grant) at price 3.41 per share. | 7K | $23.75K |
| Sep 14, 2026 | Miller Michael FrancisChief Technology Officer | — | 1.6K | — |
| Aug 30, 2026 | Miller Michael FrancisChief Technology Officer | — | 159 | — |
| Aug 18, 2026 | Elliott Jeffrey ThomasDirector | — | 4K | — |
| Aug 16, 2026 | Donnelly William PDirector | — | 2.8K | — |
| Aug 13, 2026 | Miller Michael FrancisChief Technology Officer | — | 1.6K | — |
| Aug 12, 2026 | Donnelly William PDirector | Purchase at price 2.75 - 2.93 per share. | 99.4K | $286.35K |
| Jul 30, 2026 | Miller Michael FrancisChief Technology Officer | — | 130 | — |
| Jul 14, 2026 | Miller Michael FrancisChief Technology Officer | — | 1.6K | — |
| Jul 7, 2026 | Lai-Goldman Myla PDirector | — | 8.1K | — |
| Jul 7, 2026 | Mendel ScottDirector | — | 8.1K | — |
| Jun 30, 2026 | Donnelly William PDirector | Stock Award(Grant) at price 4.34 per share. | 5.5K | $23.75K |
| Jun 30, 2026 | Mendel ScottDirector | Stock Award(Grant) at price 4.34 per share. | 3.5K | $15.00K |
| Jun 29, 2026 | Miller Michael FrancisChief Technology Officer | — | 130 | — |
| Jun 14, 2026 | Sriram VandanaChief Financial Officer | — | 1.8K | — |
| Jun 14, 2026 | Miller Michael FrancisChief Technology Officer | — | 1.6K | — |
| May 28, 2026 | Miller Michael FrancisChief Technology Officer | — | 130 | — |
| May 14, 2026 | Sriram VandanaChief Financial Officer | — | 1.8K | — |
| May 14, 2026 | Miller Michael FrancisChief Technology Officer | — | 1.6K | — |
| May 11, 2026 | Meadows BenjaminOfficer | Purchase at price 2.77 per share. | 3.5K | $9.70K |
TimeframesDown on the hourly, weekly and monthly, mixed on the daily.
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.3 | 3.3 | -46.3 | -11.1 | -2.2 | 41.2 | -19.4 | -23.3 | 39.0 | -22.6 | −54.9% | ||
| 2025 | -13.5 | -17.4 | -14.2 | -11.5 | -9.7 | 27.9 | -10.7 | -23.4 | 19.3 | -1.7 | 36.0 | -12.4 | −40.2% |
| 2024 | -19.2 | 8.5 | -1.7 | -31.6 | -0.9 | -17.3 | 11.7 | -11.7 | -0.5 | 2.0 | -6.7 | -13.8 | −61.1% |
| 2023 | 2.0 | -22.2 | 2.5 | 12.2 | 55.1 | 15.0 | 10.2 | 7.9 | 1.3 | -20.0 | 10.4 | 14.1 | +97.4% |
| 2022 | -28.2 | 10.8 | -13.5 | -24.0 | -24.0 | -4.0 | -1.2 | -41.5 | 17.9 | 0.5 | 20.1 | 4.1 | −67.3% |
| 2021 | 39.2 | 17.0 | -22.8 | 4.6 | -15.8 | 13.9 | -9.4 | -4.0 | -2.5 | 1.6 | -21.0 | 6.1 | −8.8% |
| 2020 | 14.7 | -15.9 | -19.5 | 42.6 | 5.3 | -0.7 | 18.0 | 10.2 | -5.2 | 8.5 | 18.0 | 7.7 | +96.8% |
| 2019 | 15.0 | 17.3 | 4.5 | -12.0 | 12.7 | 31.9 | -8.3 | -15.0 | -16.6 | -5.1 | 21.5 | -6.7 | +29.1% |
| 2018 | -3.1 | 0.4 | -18.4 | -0.5 | 8.6 | -22.0 | 4.4 | 11.6 | 28.0 | -18.3 | 7.0 | -2.3 | −14.7% |
| 2017 | — |
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Buy / hold / sell counts